JP2023554587A5 - - Google Patents

Info

Publication number
JP2023554587A5
JP2023554587A5 JP2023528270A JP2023528270A JP2023554587A5 JP 2023554587 A5 JP2023554587 A5 JP 2023554587A5 JP 2023528270 A JP2023528270 A JP 2023528270A JP 2023528270 A JP2023528270 A JP 2023528270A JP 2023554587 A5 JP2023554587 A5 JP 2023554587A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
fused
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081303 external-priority patent/WO2022101302A1/en
Publication of JP2023554587A publication Critical patent/JP2023554587A/ja
Publication of JP2023554587A5 publication Critical patent/JP2023554587A5/ja
Pending legal-status Critical Current

Links

JP2023528270A 2020-11-12 2021-11-10 Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 Pending JP2023554587A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20306370.6 2020-11-12
EP20306370 2020-11-12
EP21305091 2021-01-26
EP21305091.7 2021-01-26
PCT/EP2021/081303 WO2022101302A1 (en) 2020-11-12 2021-11-10 Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes

Publications (2)

Publication Number Publication Date
JP2023554587A JP2023554587A (ja) 2023-12-28
JP2023554587A5 true JP2023554587A5 (enExample) 2024-09-09

Family

ID=78599029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528270A Pending JP2023554587A (ja) 2020-11-12 2021-11-10 Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用

Country Status (8)

Country Link
US (1) US20240010739A1 (enExample)
EP (1) EP4244253A1 (enExample)
JP (1) JP2023554587A (enExample)
KR (1) KR20230107260A (enExample)
CA (1) CA3200878A1 (enExample)
CO (1) CO2023007284A2 (enExample)
MX (1) MX2023005570A (enExample)
WO (1) WO2022101302A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20210070A7 (es) * 2021-08-20 2023-03-07 Ct Ingenieria Genetica Biotecnologia Antígenos quiméricos para el control de coronavirus y composiciones que los comprenden
US20260034207A1 (en) * 2022-06-30 2026-02-05 Eps Innovative Medicine (Japan) Co., Ltd. Vaccine composition for sublingual administration

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN101657464A (zh) 2007-02-02 2010-02-24 贝勒研究院 与靶向人源化单克隆抗体复合的多变量抗原
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2685823T3 (es) 2008-07-16 2018-10-11 Baylor Research Institute Anticuerpos antagonistas anti-CD40
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
EP2477655A4 (en) 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
EA029661B1 (ru) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
US10610585B2 (en) * 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN111217917B (zh) * 2020-02-26 2020-10-23 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
CN111533809A (zh) * 2020-04-21 2020-08-14 中国科学院武汉病毒研究所 针对新型冠状病毒的亚单位疫苗及应用

Similar Documents

Publication Publication Date Title
JP2023528017A5 (enExample)
AU2004279877B2 (en) Fully human antibodies against human 4-1BB (CD137)
JP5363432B2 (ja) 樹状細胞−t細胞の相互作用を調節するための組成物及び方法
EP2406286B1 (en) Anti-cd40 antibodies and uses thereof
US7563445B2 (en) CD40 binding molecules and CTL peptides for treating tumors
CN105884903B (zh) 靶向抗原呈递细胞的疫苗
EP1434596B1 (en) Enhancement of immune responses by agonist 4-1bb-antibodies
EP3138854B1 (en) Antibodies against cd40
KR20130036246A (ko) 사람 cd8+ t 세포의 수지상 세포 면역수용체(dcir)-매개 교차프라이밍
TW200902061A (en) Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
CN113797332B (zh) 用于免疫疗法的组合物和方法
EP1599504A1 (en) Modified antibody
KR20090114466A (ko) 덱틴-1을 통한 사람 항원제시세포 활성화의 치료학적 적용
KR20090127886A (ko) 수지상 세포 렉틴 유사 산화된 ldl 수용체-1(lox-1)을 통한 사람 항원제시세포의 활성화
KR20090118981A (ko) Clec-6을 통한 사람 항원제시세포의 활성화
CN1423700A (zh) 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
JP2023554587A5 (enExample)
Tunheim et al. Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates
HK1153501A (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
HK1227905A1 (en) Antigen presenting cell targeted vaccines
HK1227905A (en) Antigen presenting cell targeted vaccines
HK1178546A (en) Antigen presenting cell targeted vaccines